ICV Value = 89.08
Dr. Richard J Jurevic is Chair in the Department of Diagnostic Services (Oral Diagnostics). He received his undergraduate and dental degrees from The Ohio State University. At the University of Washington, he completed speciality training in Oral Medicine and Radiology and fellowship in Special Care Dentistry, and his PhD in Oral Biology. Dr. Jurevic was the recipient of the NIH/NIDCR Ruth Kirschstein National Research Service Award, the NIH/NIDCR Dental Scientist Award (K16 Grant, U.Washington; 1998-2003), the Warren B. Magnusson Biomedical Research Award (U.Washington; 2000), and the Edward Wach Research Award (University of Illinois at Chicago; 2005). Dr. Jurevic was a recipient of a K23 mentored patient oriented clinical research grant entitled 'Defensin gene cluster variation and Candida carriage' for 5 years through the NIH/NIDCR. Dr. Jurevic recently completed a R01 grant as part of a program project, investigating the association of genetic variations in innate immune genes with oral manifestations of HIV /AIDS. Dr. Jurevic was also a member of the UH/Cleveland Center for AIDS Research (CFAR). He is also an oral medicine specialist and co-investigator with the ACTG (AIDS Clinical Trials Group) Oral HIV AIDS Research Alliance (OHARA) investigating oral candidiasis and new treatment modalities for underserved populations. The CASE OHARA group is also investigating the complex inter-relationships that occur in the oral cavity of the immune compromised host utilizing mycobiomic, microbiomic, and metabolomic methods to assess disease progression and associated coinfections. His work has extended into a Phase 3 clinical trial investigating the efficacy of gentian violet for the treatment of oral candidiasis in immune compromised patients. Currently Dr. Jurevic is a CTSI funded Clinical Researcher for the School of Dentistry, a member of the WVU Cancer Center, and member of the WVU Institutional Review Board. Dr. Jurevic is also responsible for managing the Oral Medicine Clinics and Oral Radiology Service for the WVU School of Dentistry. Dr. Jurevic's research interests focus on the genetic basis of oral disease. The focus of his studies is investigating the association of single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) in the epithelial expressed antimicrobial peptide family known as Defensins. Dr. Jurevic has developed high-throughput genetic assays to study the association of these variations on susceptibility for oral diseases such as candidiasis in high risk populations for clinical application. He is currently investigating the relationship of defensin peptide expression patterns in patients undergoing cytotoxic chemotherapies and assessing the relationship of genetic variation and expression of peptide with development and severity of oral mucositis associated with cytotoxic cancer chemotherapies. He is also collaborating with the Department of Orthopedic Surgery studying the relationship and species characterization of complex oral biofilms and development of biofilms on implantable knee prostheses by pyrosequncing technologies. His lab is also developing point of care assays to monitor dental implant failure by evaluating changes in chemokine and cytokine profiles longitudinally by electromagnetic ELISA methods. The translational aspects of his research will facilitate the development of clinically applicable assessment tools for future patient care.